Business Wire

GWI Revolutionizes Market Research With Brand-new Platform, Democratizing Access to Impactful Audience Insights

Share

GWI, the leading target audience insight company, today launches its brand-new platform that challenges the status quo in market research. The multi-million dollar investment into the new platform provides access to transformational insights, in a meaningful and visual way. Arming employees with one, consistent in-depth view of their global or local audience, the new capabilities power strategic decisions and enable deep understanding of diverse and evolving audiences.

The new platform makes it easy to be an expert on your audience with smart tools that make it simple to explore available datasets. Users are now able to rapidly access deep insights, answering the questions that matter most to make key business decisions based on facts they can trust. It aids businesses to be truly data-driven by putting accessible insights and bespoke dashboards into the hands of everyone across the organization - from decision makers in the C-suite to data analysts, researchers and marketers.

Tom Smith, CEO and Founder at GWI comments, “The new platform enables a new dawn for the future of marketing research, ensuring it is suited for today's environment which consists of rapid change of pace for business and consumers. Our data shows that 72%* of professionals globally agree that being able to adapt quickly is critical to their company’s long term success. Yet, the traditional market research industry has utterly failed the needs of its customers in today's global marketplace - a world where almost 5 billion people are permanently connected online. Uncovering really transformative insight isn’t easy, nor is it always ‘on time’. Traditional research often takes several months, and can be delayed throughout the process. Despite heavy investment, the insights can therefore quickly become outdated, whilst putting market research out of reach for nearly every single organisation.

“With our new platform combined with our tried and tested methodology, you can secure insights and answers in an instant versus a drawn out process, at a fraction of the traditional market research cost. At the same time, you can ensure organizational alignment, meaning everyone is working from a single source of truth - to tell the same story, inform the decisions that matter and deliver impactful results.”

The intuitive new platform provides access to the world’s largest harmonized ongoing study on digital consumers, representing 2 billion people globally. Users of the flagship survey, GWI Core, alone can gather insights from over 40,000 data points, from over 800,000 interviews. The new platform will foster smarter business decisions and outcomes using hyper-targeted insights into any consumer group, in local and global markets.

To learn more about the new platform including new features and capabilities or to book a demo please visit here.

ENDS

About GWI

GWI is the leading supplier of target audience insight to the global marketing industry.

Trusted by the world’s biggest brands, media organizations, and agencies on a daily basis to get closer to their audiences, the company’s flagship survey represents over 2 billion people globally. Using the subscription-based platform, clients like Twitter, Google, Spotify, WPP, IPG, and Omnicom Group gather in-depth insights into behaviors, attitudes, and interests in seconds through a combination of survey data and analytics.

Among a range of leading data products available alongside its flagship survey are:

  • GWI USA is a deep dive into the habits, behaviors and attitudes of 240m internet users in the USA.
  • GWI Gaming delves into the actions and attitudes of gamers across 15 markets.
  • GWI Sports investigates sports fandom and participation across 15 markets.
  • GWI Kids gets to the heart of how kids actually think, so you can be sure to kid-proof your ideas and concepts from here on.
  • GWI Work gives a detailed view of the lives of business professionals across 10 markets.
  • GWI Zeitgeist, included with our core survey, is fielded monthly and zeroes in on the stuff that matters. It’s topical, timely, and relevant.

Those looking for even more bespoke research solutions can enrich GWI data with a range of services like hyper-targeted custom surveys, brand trackers, and recontact studies.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contact:
Liam Rawson
Hotwire Global
gwi@hotwireglobal.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

HiddenA line styled icon from Orion Icon Library.Eye